Compare Merck & Co., Inc. (MRK) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard International High Dividend Yield ETF — how do they compare? Merck & Co., Inc. trades at $133.7 (market cap $321.77B), while Vanguard International High Dividend Yield ETF trades at $104.53. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals.
| MRK | VYMI | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $131.84 | $105.05 |
52-Week Low | $77.60 | $82.92 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
VYMI, the Vanguard International High Dividend Yield ETF, trades at $104.48, down slightly by 0.11% today. The technical outlook is bullish based on moving averages, with key support at $104 and resistance at $105. Recent news highlights strong institutional buying and its appeal to retirees seeking international dividend income, with the fund outperforming the S&P 500 over the past five years.
The ETF offers a compelling income play with a 3.4% dividend yield and an 8.86% five-year dividend CAGR, supported by bullish analyst sentiment. Risks include currency fluctuations from international exposure and broader market volatility, but its diversification and high yield provide a defensive stance amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
